相关实验视频

Updated: Jan 15, 2026

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

免疫检查点抑制剂在高度的胃肠道胰腺神经内分泌瘤中

Nicola Fazio¹, Anna La Salvia²

¹Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, IT.

Endocrine reviews

|October 9, 2025

概括

高度的胃肠道瘤神经内分泌瘤 (HG-NENs) 显示出免疫检查点抑制剂 (ICI) 的前景,因为瘤突变负担较高. 需要进一步的研究,以优化ICI治疗选择这些具有挑战性的癌症.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
胃肠道胰腺神经内分泌新生体胃肠道胰腺神经内分泌新生体

背景情况:

高度的胃肠道瘤神经内分泌瘤 (HG-NENs) 包括3级神经内分泌瘤 (NETs) 和神经内分泌癌 (NECs),呈现出明显的临床管理挑战.
目前对先进的NEC (加乙) 的一线治疗对G3 NET来说并不理想,因为其他治疗方法的疗效有限.
HG-NENs具有更高的瘤突变负担 (TMB),增加PD-1/PD-L1表达和更大的免疫透等生物特征,这表明它们可能适用于免疫检查点抑制剂 (ICI).

研究的目的:

提供关于免疫检查点抑制剂 (ICI) 在高度胃肠道瘤神经内分泌瘤 (HG-NENs) 中的作用的综合文献综述.
分析现有临床试验的关键方面,涉及HG-NEN中的ICI,包括患者群体,研究设计和结果.
确定潜在的生物标志物来选择可能从ICI治疗中受益的HG-GEP-NEN患者.

主要方法:

对研究免疫检查点抑制剂 (ICI) 在高度胃肠道胰腺神经内分泌瘤 (HG-NENs) 中的临床试验的系统性文献综述.
分析重点是研究人群,试验设计,疗效和安全结果.
在HG-NEN中评估ICI反应的潜在预测生物标志物.

主要成果:

有限的临床试验已经在HG-NEN中探索了ICI,因此需要对当前数据进行全面的概述.
对研究群体,设计和结果的分析对于理解ICI在这种情况下的有效性和安全性至关重要.
生物标志物的识别对于患者分层和优化HG-NENs中的ICI治疗选择至关重要.

结论:

高度的胃肠道瘤神经内分泌瘤 (HG-NENs) 提供了一个探索免疫检查点抑制剂 (ICI) 的理由,因为它们的免疫性特征.
需要对现有文献进行彻底的分析,以评估ICI在HG-NEN中的有效性和安全性.
专注于生物标志物发现的进一步研究对于HG-NEN患者的个性化ICI治疗策略至关重要.

关键词:

有效性有效性有效性.高等级的神经内分泌新生体.免疫检查点抑制剂免疫检查点抑制剂在安全方面,安全是安全的.

更多相关视频

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...